当前位置: 首页 SCI期刊 SCIE期刊 医学 中科院4区 JCRQ3 期刊介绍(非官网)
Oncotargets And Therapy

Oncotargets And TherapySCIE

国际简称:ONCOTARGETS THER  参考译名:肿瘤靶点和治疗

  • 中科院分区

    4区

  • CiteScore分区

    Q1

  • JCR分区

    Q3

基本信息:
ISSN:1178-6930
E-ISSN:1178-6930
是否OA:开放
是否预警:是
TOP期刊:否
出版信息:
出版地区:ENGLAND
出版商:Dove Medical Press Ltd.
出版语言:English
出版周期:1 issue/year
出版年份:2008
研究方向:BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY
评价信息:
影响因子:2.7
H-index:44
CiteScore指数:9.7
SJR指数:0.81
SNIP指数:0.648
发文数据:
Gold OA文章占比:96.46%
研究类文章占比:56.00%
年发文量:75
自引率:0
开源占比:0.9788
出版撤稿占比:0.0179...
出版国人文章占比:0.86
OA被引用占比:1
英文简介 期刊介绍 CiteScore数据 中科院SCI分区 JCR分区 发文数据 常见问题

英文简介Oncotargets And Therapy期刊介绍

OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents

-Novel therapeutic regimens for improved benefit and/or decreased side effects

-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.

-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.

-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.

-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Single nucleotide polymorphism (SNP) studies will not be considered.

期刊简介Oncotargets And Therapy期刊介绍

《Oncotargets And Therapy》自2008出版以来,是一本医学优秀杂志。致力于发表原创科学研究结果,并为医学各个领域的原创研究提供一个展示平台,以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述,从广泛的视角提供当前感兴趣的研究主题的新见解,或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年被列入预警期刊名单,目前已被权威数据库SCIE收录,得到了广泛的认可。

该期刊投稿重要关注点:

Cite Score数据(2024年最新版)Oncotargets And Therapy Cite Score数据

  • CiteScore:9.7
  • SJR:0.81
  • SNIP:0.648
学科类别 分区 排名 百分位
大类:Medicine 小类:Pharmacology (medical) Q1 23 / 272

91%

大类:Medicine 小类:Oncology Q1 65 / 404

84%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础,针对的是前四年发表的论文的引文。CiteScore的意义在于,它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法,而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Oncotargets And Therapy 中科院分区

中科院 2023年12月升级版 综述期刊:否 Top期刊:否
大类学科 分区 小类学科 分区
医学 4区 BIOTECHNOLOGY & APPLIED MICROBIOLOGY 生物工程与应用微生物 ONCOLOGY 肿瘤学 3区 4区

中科院分区表 是以客观数据为基础,运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据,得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次,类似于“优、良、及格”等。最开始,这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Oncotargets And Therapy JCR分区

2023-2024 年最新版
按JIF指标学科分区 收录子集 分区 排名 百分位
学科:BIOTECHNOLOGY & APPLIED MICROBIOLOGY SCIE Q3 90 / 174

48.6%

学科:ONCOLOGY SCIE Q3 163 / 322

49.5%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:BIOTECHNOLOGY & APPLIED MICROBIOLOGY SCIE Q2 73 / 174

58.33%

学科:ONCOLOGY SCIE Q2 135 / 322

58.23%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异,此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此,JCR将期刊按照学科门类和影响因子分为不同的分区,这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计
  • 国家/地区数量
  • CHINA MAINLAND2784
  • USA135
  • Italy44
  • Japan32
  • Taiwan26
  • South Korea25
  • GERMANY (FED REP GER)23
  • Spain12
  • France10
  • Iran10

本刊中国学者近年发表论文

  • 1、Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report

    Author: Zhang, Xiangming; Ni, Kai; Chen, Huijun

    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 87-90. DOI: 10.2147/OTT.S393165

  • 2、Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer

    Author: Wang, Jia-Wei; Yuan, Qing; Li, Li; Cao, Kai-Hua; Liu, Qi; Wang, Hong-Liang; Hu, Ke; Wu, Xi; Wan, Jing-Hai

    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 179-187. DOI: 10.2147/OTT.S402389

  • 3、Secondary Sinonasal Collision Tumor of Papillary Squamous Cell Carcinoma and Small Cell Neuroendocrine Carcinoma After Nasopharyngeal Carcinoma Radiotherapy: A Case Report and Literature Review of Sinonasal Collision Carcinomas

    Author: Tang, Hao; Wang, Lina; Xu, Wenfeng; Xu, Yujuan; Li, Xianyun; Guo, Deyu

    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 91-97. DOI: 10.2147/OTT.S396703

  • 4、Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK-LIMS1 Fusion: A Case Report

    Author: Shi, Junmei; Jia, Zhaohui; Zhou, Zhiguo; Zhao, Liyan; Meng, Qingju; Liu, Yibing

    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 109-114. DOI: 10.2147/OTT.S388962

  • 5、Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study

    Author: Li, Guiling; Cheng, Mingxia; Hong, Kai; Jiang, Yao

    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 157-163. DOI: 10.2147/OTT.S400376

  • 6、A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review

    Author: Li, Dan; Liu, Xin; Cui, SaiQiong; Yang, DaFu; Zhu, Yue; Pan, Evenki; Yang, Peng; Dai, ZhaoXia

    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 17-22. DOI: 10.2147/OTT.S391766

  • 7、Transmission of Exosomal TPX2 Promotes Metastasis and Resistance of NSCLC Cells to Docetaxel

    Author: Hu, Jiaru; He, Qing; Tian, Tian; Chang, Na; Qian, Liting

    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 197-210. DOI: 10.2147/OTT.S401454

  • 8、A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib

    Author: Fan, Weiming; Wang, Chuan; Zhong, Xuefeng; Zheng, Yating; Chen, Tingting; Huang, Mengli; Su, Shuying

    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 23-29. DOI: 10.2147/OTT.S390458

投稿常见问题

通讯方式:PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752。